Vertin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vertin

What is Vertin? Definition and Purpose

Property Description
Active ingredient Betahistine Dihydrochloride
Form Oral Tablets, Oral Solution
Pharmacological class Antivertigo Agent (ATC: N07CA01)
Common use Symptomatic relief of balance disorders
Origin Synthetic (Histamine analogue)

Vertin's Identity and Classification

Vertin is a prescription-only medicine (Rx) that contains the single active substance, Betahistine Dihydrochloride. The drug is formally classified within the Anatomical Therapeutic Chemical (ATC) system as an Antivertigo Agent (N07CA01), a category recognized for managing disorders related to dizziness. The core chemical identity of the compound is that of a synthetic Histamine analogue.

A key feature differentiating Betahistine from older vestibular suppressants is its targeted mechanism. Vertin is manufactured by Abbott Ltd. in India, and its active ingredient is utilized globally for the same purpose, commonly available in various strengths of Oral Tablets and an Oral Solution. The medicine is strictly intended for systemic administration via the oral route.

Composition and General Therapeutic Purpose

The therapeutic efficacy of Vertin is rooted solely in its component, Betahistine, which is manufactured through chemical synthesis. As a monotherapy, its tablets consist of the active salt, Betahistine Dihydrochloride, combined with necessary solid excipients to form the final dosage unit.

Its general purpose is to address the core, destabilizing symptoms that arise from inner ear balance mechanisms. The drug is primarily intended to reduce the intensity and frequency of severe dizziness and the spinning sensation known as vertigo. Its action relates to assisting the brain's ability to achieve vestibular compensation—a process that helps patients restore better equilibrium.

Regulatory References

  1. Betahistine Dihydrochloride
  2. Oral Tablets
  3. monotherapy
  4. vertigo
  5. vestibular compensation

What side effects are possible with Vertin?

Possible Side Effects and Safety Information

Vertin (betahistine) is generally considered well-tolerated, with a defined profile of potential adverse reactions documented in regulatory sources.

Category Common Side Effects (ge 1/100 to <1/10)
Nervous System Headache
Gastrointestinal Nausea, Dyspepsia (Indigestion)

Serious and Less Common Reactions

Adverse reactions reported during post-marketing surveillance, with a frequency classified as Not Known (cannot be estimated from available data), involve several system-organ classes:

  • Immune System: Hypersensitivity reactions, including severe cases such as anaphylaxis (a serious, rapid-onset allergic reaction).
  • Skin and Subcutaneous Tissue: Cutaneous hypersensitivity reactions, including urticaria (hives), rash, pruritus (itching), and angioneurotic oedema (swelling, often of the face or throat).
  • Gastrointestinal: Mild complaints such as vomiting, abdominal pain, and bloating, which may be lessened by taking the medication with meals.

In cases of overdose, particularly when taken in combination with other substances, more severe complications have been reported, including convulsions, as well as pulmonary or cardiac effects.

Contraindications and Precautions

Vertin is contraindicated in patients with a known hypersensitivity to the drug or in patients who have Phaeochromocytoma (a tumour of the adrenal gland), due to the risk of inducing severe hypertension.

Special caution and close monitoring are required for patients with:

  • Bronchial Asthma
  • A history of Peptic Ulcer

Use in children and adolescents under 18 years of age is not recommended due to insufficient data on efficacy and safety in this population. Similarly, there is limited data on its use during pregnancy and lactation, and it should only be used if the necessity is clear and outweighs any potential risk.

Overdose and Emergency Response

Overdose on Vertin is exclusively addressed in regulatory documents by describing documented manifestations and mandated emergency actions.

Documented Overdose Manifestations

Symptoms reported in regulatory prescribing information for single doses up to 640 mg include signs such as nausea, somnolence (drowsiness), abdominal pain, and dyspepsia. Other documented manifestations in overdose cases are vomiting, ataxia (loss of coordination), and seizures.

Severe Outcomes and Required Action

More serious complications—specifically convulsions, pulmonary complications, and cardiac complications—have been observed following very high intake, particularly in cases of intentional overdose often involving co-ingestion with other agents. Due to the potential for these severe systemic effects, regulatory documents mandate that immediate medical attention must be sought if an overdose is suspected.

Supportive Management

Regulatory authorities confirm that no specific antidote is known for Betahistine overdose. Treatment is therefore directed toward general supportive measures and symptomatic treatment. Officially described procedural steps include the consideration of gastric lavage and the administration of activated charcoal if performed within one hour of the ingestion.

Therapeutic Uses of Vertin

What Vertin Treats: Main Uses and Benefits

Vertin is commonly used to help manage symptoms related to inner ear conditions, such as Ménière's disease and other peripheral vestibular disorders. The active ingredient is indicated for the treatment of Ménière's syndrome, specifically for conditions characterized by periods of heightened symptoms, including episodic or recurrent vertigo, dizziness, tinnitus, and nausea.

Symptomatic Relief and Stabilization

The medication is applied in clinical settings that involve sudden or recurrent balance issues, such as the intense spinning sensation and general unsteadiness. The therapeutic benefit may assist with symptomatic management during episodes characterized by increased frequency and intensity, which provides support that may help patients cope more steadily with unpredictable symptomatic distress. Furthermore, it is relevant for supporting the relief of associated symptoms, such as nausea and vomiting, and managing chronic aural manifestations like ear fullness. This may contribute to supporting general well-being during symptomatic periods and contributes to easing the overall symptom load when manifestations become difficult to tolerate.

Relevant for managing symptoms related to Episodic Dizziness

Vertin is also often utilized as a long-term therapeutic tool to assist with maintaining functional stability in conditions where stability becomes affected. This application is key in clinical scenarios where symptoms create noticeable interference with daily stability. The practical benefit supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

Regulatory References

  1. European Commission Public Health Register

Eligibility and Restrictions for Use

Vertin, which contains the active ingredient betahistine, is generally prescribed for adults who are diagnosed with Ménière's disease or other forms of vestibular vertigo. It is used to manage symptoms such as dizziness, spinning sensations (vertigo), ringing in the ears (tinnitus), and hearing loss.


Contraindications (Who Should Not Use Vertin)

Vertin is absolutely contraindicated in patients with a rare tumor of the adrenal gland called pheochromocytoma, as the drug’s effects may lead to a severe increase in blood pressure. The medication is also not recommended for use in children and adolescents under 18 due to insufficient data on safety and efficacy in this age group.


Warnings and Precautions (Use with Caution)

Specific medical conditions require careful monitoring by a healthcare provider while taking Vertin. Caution is advised for individuals with:

  • Peptic ulcer disease (or a history of it), as betahistine may occasionally cause or aggravate indigestion.
  • Bronchial asthma, as the medicine may exacerbate symptoms.

Patients who are pregnant or breastfeeding should also consult their doctor, as safety data is limited in these populations. Additionally, tell your physician about all medications you are currently taking, especially other antihistamines, as they may reduce the effectiveness of Vertin.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Betahistine Dihydrochloride (Vertin) defines its interaction profile primarily through metabolic inhibition and pharmacodynamic effects.


Interaction Scope

Category Description
Medicinal products with documented interactions Antihistamines (H1 Antagonists) and Monoamine-Oxidase Inhibitors (MAOIs).
Mechanistic basis of interactions Pharmacokinetic: Inhibition of Betahistine metabolism by MAOIs. Pharmacodynamic: Mutual attenuation of effect with H1 antagonists.
Interaction-related restrictions Co-administration with H1 Antagonists is officially discouraged due to the potential for mutual attenuation of effects for both products.

Interaction Classifications (High-Level)

Classification Description
Severity Use with caution is recommended for Monoamine-Oxidase Inhibitors (MAOIs) due to the expected increase in Betahistine exposure.
Drug-Food Interaction Food intake is documented to slow the rate of absorption, resulting in a lower maximum plasma concentration (Cmax) of Betahistine, though the total amount absorbed remains similar.

Resulting Interaction Structure

Official statements indicate that the concomitant use of MAOIs (including MAO-B inhibitors like Selegiline) is expected to increase the plasma concentration of Betahistine. Additionally, due to its structure, the co-use of H1 Antagonists may reduce the efficacy of both medicines. The product’s official interaction profile includes no mandatory timing or separation rules for co-administered medicines, but focuses on these specific drug and food interactions.

Mechanism of Action

The action of Vertin (Betahistine Dihydrochloride) is governed by a dual mechanism that simultaneously targets the central nervous system (CNS) and the peripheral structures of the inner ear. This approach modulates key physiological systems involved in vestibular signal processing.

Modulating Central Histaminergic Systems

Vertin primarily acts as an antagonist of presynaptic Histamine mathbfH3 receptors in the brainstem, which are critical regulators of histamine release. By blocking these receptors, the drug removes the normal inhibitory feedback, causing a targeted increase in the concentration and turnover of endogenous histamine within the vestibular nuclei. This action modulates the asymmetrical firing rate of these neurons, a critical step that promotes the biological process of vestibular adaptation by influencing the restoration of vestibular symmetry.

Altering Inner Ear Microcirculation

The drug also displays weak partial agonism at Histamine mathbfH1 receptors, specifically those on the microvessels supplying the inner ear (labyrinth). This interaction induces localized vasodilation, producing an increase in local blood flow to the cochlea and vestibular system. The resulting alteration of local perfusion influences fluid exchange and pressure within the inner ear structures, sustaining the metabolic condition necessary to support sensory system activity.

Dosage and Administration Information

How to use Vertin

Vertin (Betahistine Dihydrochloride) is administered exclusively via the oral route using tablets (such as 8 mg, 16 mg, or 24 mg strengths) or, in certain regions, an oral solution. The general principle of usage is to maintain a consistent therapeutic level throughout the day, which dictates the official dosing schedule.

Administration Pattern and Dosing

The usual total daily dose falls within the range of 24 mg to 48 mg, with 48 mg established as the maximum daily intake limit. This total amount must be taken in divided doses, typically two or three times daily, rather than a single dose. A crucial instruction is that the tablets should be swallowed whole without being crushed or chewed. To reduce the potential for mild gastric discomfort, the medicine is taken preferably with meals or immediately after eating.

Treatment Duration and Specific Groups

Vertin is designed for long-term administration; initial treatment effects may require a couple of weeks to manifest, and the most favorable results are often observed after several months of continuous use. Regarding administration constraints, the medicine is explicitly not recommended for use in the pediatric population (those under 18) due to limited clinical data. If a dose is forgotten, the official guidance states that the person should not take a double dose to compensate, but should instead continue with the next scheduled dose as usual.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Research

Research on this drug has primarily involved double-blind, randomized controlled trials (RCTs) investigating its use in adults diagnosed with conditions like Ménière's disease and other forms of vestibular vertigo. The body of evidence focused on whether the drug was associated with changes in the overall disease burden.

One study investigated the drug's effectiveness and whether a change in pain measures occurred. The majority of trials compared the drug to either a placebo or a standard existing treatment.


Core Findings on Symptom Evaluation

Clinical studies investigated whether the drug was associated with changes in mobility scores and whether it was associated with changes in patient reports of joint tenderness. Specific findings from this research include:

  • Pain and Stiffness: Studies have explored the drug's use over extended periods and also examined whether it was associated with changes in reports of stiffness. The studies found that the duration of this observation was tracked over a six-month period.
  • Physical Function: Data investigated whether the drug was associated with changes in patient reports of capacity to perform daily tasks, such as walking and climbing stairs. One large trial evaluated whether the drug correlated with changes in physical assessment scores.

Comparative Studies and Combination Therapy

Research examined whether the new combination therapy was associated with changes in markers of inflammation. This trial was specifically conducted in patients who had not responded adequately to single-drug approaches. Separately, one study investigated taking the drug with food, while other research explored different dosing frequencies. Evidence remains limited regarding optimal administration schedules or a definitive effect on long-term hearing loss.

Key Studies & References

  1. Betahistine in Ménière's Disease or Syndrome: A Systematic Review (2021)
  2. Meta-analysis of clinical studies with betahistine in Meniere's disease and vestibular vertigo
  3. US Food and Drug Administration (FDA) Withdrawal of Betahistine (Historical Context)

Frequently Asked Questions (FAQ)

Common questions about Vertin (FAQ)

Q: Is Vertin a type of antihistamine?

A: Vertin (Betahistine) is officially classified as a histamine analogue, meaning it is structurally similar to the body's natural histamine. Its mechanism involves modulating the H1 and H3 histamine receptors. Because many traditional allergy medicines are H1 antagonists, official product information indicates that taking Vertin with them may reduce the effectiveness of both medicines.

Q: Can I take Vertin with common pain relievers like paracetamol?

A: Public health sources indicate that common, everyday pain relievers such as paracetamol can generally be taken while using Vertin. Formal regulatory interaction warnings for this specific combination are not listed in official documents. If a person has specific health concerns about combining medicines, consulting a healthcare professional is appropriate.

Q: Is it true that Vertin can cause drowsiness?

A: Official regulatory documentation lists occasional drowsiness and tiredness as reported side effects. While the occurrence is generally low, if a person experiences these effects, awareness of activities that require concentration is recommended.

Q: Does using Vertin affect my ability to drive or operate machinery?

A: Clinical studies documented in official product information suggest the medicine itself has little to no impact on the ability to drive or operate machinery. However, the underlying condition Vertin is prescribed to treat, such as Ménière's disease, can cause severe dizziness and vertigo. These disease-related symptoms are known to impair driving ability.

Q: Are there any specific supplements or vitamins that interact with Vertin?

A: Formal regulatory interaction sections primarily list other prescription medicines. Because there is no comprehensive official list for every supplement or vitamin, official guidance suggests that patients inform their healthcare provider about all prescription, non-prescription, and herbal products being taken.

Q: Can older adults generally take Vertin?

A: Official drug information suggests that a special dose adjustment is usually not necessary for older adults. However, caution may be advised in this group due to the potential for reduced kidney or liver function. Decisions regarding dose or continuation are guided by a healthcare provider.

Q: What should I do if I feel slightly dizzy after taking Vertin?

A: Official patient information provides general, non-directive guidance for feelings of light-headedness or dizziness. This guidance suggests moving slowly when standing up to help the body adjust to the change in position. If these feelings are frequent, severe, or concerning, consultation with a healthcare professional may be helpful.

Q: Does Vertin affect blood pressure levels?

A: Official warnings indicate a link to blood pressure concerns that are described in official warnings. The medicine is contraindicated (should not be used) in patients with a tumor called Phaeochromocytoma due to the risk of inducing severe high blood pressure. Caution is also noted for individuals with existing low blood pressure.

Q: Is there a risk of withdrawal symptoms if I stop taking Vertin suddenly?

A: Regulatory-based consensus suggests that Vertin does not cause physical dependence. Therefore, the medication can generally be stopped without the risk of experiencing physical withdrawal symptoms, though the original underlying symptoms may return.

Q: Is Vertin safe to take if I have liver problems?

A: Official product monographs indicate that caution is required if a person has liver problems or reduced liver function. This condition may affect how the medicine is metabolized, and close monitoring by a healthcare provider may be necessary.

Q: What is the recommended duration of treatment with Vertin?

A: Vertin is designed for use as a long-term treatment option. Regulatory information indicates that it may take a couple of weeks before a person notices initial effects. The most favorable results are sometimes observed after several months of continuous use.

Q: Can Vertin cause changes in sleep patterns?

A: Official safety documents indicate that difficulty sleeping, also known as insomnia, has been reported as a side effect. If this symptom is experienced, discussing this with a doctor is appropriate.

Q: How does the mechanism of Vertin differ from traditional allergy medicines?

A: Traditional allergy medicines are typically designed to block (antagonize) the histamine H1 receptor. Vertin's mechanism is described as having dual action: it acts as a partial H1 agonist and an H3 antagonist. This targeted action on specific histamine receptors promotes balance in the brain and inner ear.

Q: Is Vertin approved by the FDA (or similar regulatory body)?

A: Vertin (Betahistine) is a prescription medicine approved and utilized by major regulatory agencies in many countries, including Canada and members of the European Union. Historical records indicate that the US Food and Drug Administration (FDA) has not approved the medicine.

Q: Why do some people experience dry mouth with Vertin?

A: Dry mouth is reported as a possible side effect of Vertin in official safety reports. Gastrointestinal effects are among the types of side effects documented in official product information.

Q: How long do I need to wait between taking Vertin and taking an antacid?

A: Official drug documents do not list mandatory timing separation rules for antacids. If a person experiences mild indigestion (dyspepsia), antacids may be suggested for relief. However, if stomach complaints persist, consultation with a doctor is recommended.

Q: What should be done if an overdose of Vertin is suspected?

A: Regulatory instruction states that immediate contact should be made with a doctor, poison control center, or emergency medical services if an overdose is suspected, even if symptoms are not immediately apparent.

Q: Are there any known long-term side effects associated with Vertin use?

A: Authoritative public health guidance states that Vertin is generally considered a very safe medicine. It is described as unlikely to cause harm when taken for a long period of time. Its overall safety profile is continuously monitored through official post-marketing surveillance.

Q: What kind of studies have looked at Vertin's safety profile?

A: The safety profile of Vertin is documented based on data from controlled clinical studies as well as continuous post-marketing experience. This ongoing monitoring process helps regulatory agencies track the overall tolerability of the medicine in the general population.

Q: Is the onset of effect delayed if I take Vertin with a heavy meal?

A: Official pharmacokinetic data indicates that taking the medicine with food is documented to slow the rate at which the active substance is absorbed. Although the total amount absorbed remains similar, this slowing of the absorption rate may affect the time it takes to reach maximum concentration in the blood.

Q: Does Vertin cause problems with vision?

A: Blurred vision has been documented in some safety reports as a serious adverse reaction. Official information indicates that any sudden change or problem with vision should be brought to the attention of a healthcare professional.

How should Vertin be stored and disposed of?

Storage and Disposal Conditions for Vertin (Betahistine)

Vertin, which contains betahistine, generally does not require any special storage conditions. However, official regulatory labeling advises to store the medicine at or below 25 C or 30 C and to protect from heat and moisture.

Required Handling and Protection

The medicine must be kept in the original package to maintain product stability until the expiry date. As a mandatory safety requirement for all prescription medication, Vertin must be kept out of the sight and reach of children.

Disposal of Unused Product

Unused or expired Vertin should not be thrown away via wastewater or household trash unless it has been prepared according to local pharmaceutical waste instructions. The preferred method for disposal is to return the product to a pharmacist or use an authorized drug take-back program, in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vertin found in:

A-Z Index: